AU2006214138A1 - Antiangiogenic agents with aldesleukin - Google Patents

Antiangiogenic agents with aldesleukin Download PDF

Info

Publication number
AU2006214138A1
AU2006214138A1 AU2006214138A AU2006214138A AU2006214138A1 AU 2006214138 A1 AU2006214138 A1 AU 2006214138A1 AU 2006214138 A AU2006214138 A AU 2006214138A AU 2006214138 A AU2006214138 A AU 2006214138A AU 2006214138 A1 AU2006214138 A1 AU 2006214138A1
Authority
AU
Australia
Prior art keywords
aldesleukin
ril
amine
cells
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2006214138A
Other languages
English (en)
Inventor
Sharon Lea Aukerman
Kimberly Denis-Mize
Laurence Elias
Bahija Jallal
Daniel Menezes
Gary W. Witherell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Novartis Vaccines and Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines and Diagnostics Inc filed Critical Novartis Vaccines and Diagnostics Inc
Publication of AU2006214138A1 publication Critical patent/AU2006214138A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
AU2006214138A 2005-02-18 2006-02-17 Antiangiogenic agents with aldesleukin Abandoned AU2006214138A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65434105P 2005-02-18 2005-02-18
US60/654,341 2005-02-18
PCT/US2006/005720 WO2006089150A2 (fr) 2005-02-18 2006-02-17 Agents anti-angiogeniques comportant de l'aldesleukine

Publications (1)

Publication Number Publication Date
AU2006214138A1 true AU2006214138A1 (en) 2006-08-24

Family

ID=36569884

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006214138A Abandoned AU2006214138A1 (en) 2005-02-18 2006-02-17 Antiangiogenic agents with aldesleukin

Country Status (10)

Country Link
EP (1) EP1853302A2 (fr)
JP (1) JP2008530239A (fr)
KR (1) KR20070108909A (fr)
CN (1) CN101146549A (fr)
AU (1) AU2006214138A1 (fr)
BR (1) BRPI0608880A2 (fr)
CA (1) CA2598448A1 (fr)
MX (1) MX2007010037A (fr)
RU (1) RU2007134570A (fr)
WO (1) WO2006089150A2 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101497607B (zh) * 2008-01-29 2012-11-28 上海百灵医药科技有限公司 舒尼替尼的合成方法
EP2149565A1 (fr) * 2008-07-24 2010-02-03 Bayer Schering Pharma AG Dérivés de chinazoline substitués par du sulfonamide en tant que modulateurs d'immunité pour le traitement de inflammations et allergies
US9045453B2 (en) 2008-11-14 2015-06-02 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
EA020117B1 (ru) * 2008-11-14 2014-08-29 Консерт Фармасьютикалс Инк. Замещенные диоксопиперидинилфталимидные производные
PL2473487T3 (pl) 2009-09-03 2017-07-31 Bristol-Myers Squibb Company Chinazoliny jako inhibitory kanałów jonowych potasowych
WO2012079075A1 (fr) 2010-12-10 2012-06-14 Concert Pharmaceuticals, Inc. Dérivés de phtalimide deutérés
WO2013130849A1 (fr) 2012-02-29 2013-09-06 Concert Pharmaceuticals, Inc. Dérivés de phthalimide dioxopipéridinyle substitués
EP2838879A1 (fr) 2012-04-20 2015-02-25 Concert Pharmaceuticals Inc. Rigosertib deutéré
US9145411B2 (en) 2012-08-02 2015-09-29 Asana Biosciences, Llc Substituted amino-pyrimidine derivatives
EP2922838B1 (fr) 2012-10-22 2018-03-14 Concert Pharmaceuticals Inc. Formes solides de {s-3-(4-amino-1-oxo-isoindolin-2-yl)(piperidin-3,4,4,5,5-d5)-2,6-dion}
WO2014110322A2 (fr) 2013-01-11 2014-07-17 Concert Pharmaceuticals, Inc. Dérivés substitués de dioxopipéridinyl phtalimide
WO2014127214A1 (fr) 2013-02-15 2014-08-21 Kala Pharmaceuticals, Inc. Composés thérapeutiques et utilisations de ceux-ci
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
AU2014219024B2 (en) 2013-02-20 2018-04-05 KALA BIO, Inc. Therapeutic compounds and uses thereof
WO2014170910A1 (fr) 2013-04-04 2014-10-23 Natco Pharma Limited Procédé de préparation du lapatinib
AU2014342042B2 (en) 2013-11-01 2017-08-17 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
KR101478925B1 (ko) 2013-12-31 2015-01-08 아주대학교산학협력단 프로테아좀 저해제와 로페라마이드를 유효성분으로 함유하는 암질환 예방 또는 치료용 약학조성물
CA3036336A1 (fr) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Formes cristallines de composes therapeutiques et leurs utilisations
BR112019004463A2 (pt) 2016-09-08 2019-05-28 Kala Pharmaceuticals Inc formas cristalinas de compostos terapêuticos, seus processos de obtenção e seus métodos de uso
US10392399B2 (en) 2016-09-08 2019-08-27 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CN108069913B (zh) * 2016-11-18 2022-03-01 陕西师范大学 双(吗啉基烷氧基)喹唑啉衍生物及其在抗肿瘤方面的用途
WO2020102195A1 (fr) 2018-11-13 2020-05-22 Biotheryx, Inc. Isoindolinones substituées
CN114920704B (zh) * 2019-07-26 2023-11-03 暨南大学 一种苯基哌嗪喹唑啉类化合物或其药学上可接受的盐、制法与用途
CN111499583B (zh) * 2020-05-22 2022-02-15 沈阳工业大学 喹唑啉衍生物及其作为抗肿瘤药物的应用
CN112538071A (zh) * 2020-11-30 2021-03-23 新乡医学院第一附属医院 用作raf-1抑制剂的化合物、制备方法和用途

Also Published As

Publication number Publication date
RU2007134570A (ru) 2009-03-27
EP1853302A2 (fr) 2007-11-14
JP2008530239A (ja) 2008-08-07
KR20070108909A (ko) 2007-11-13
BRPI0608880A2 (pt) 2010-02-02
MX2007010037A (es) 2008-02-15
WO2006089150A3 (fr) 2006-11-02
WO2006089150A2 (fr) 2006-08-24
CA2598448A1 (fr) 2006-08-24
CN101146549A (zh) 2008-03-19

Similar Documents

Publication Publication Date Title
AU2006214138A1 (en) Antiangiogenic agents with aldesleukin
JP6263468B2 (ja) Ｍｅｋ阻害剤およびオーロラａキナーゼの選択的阻害剤の組み合わせ
JPWO2008111441A1 (ja) 医薬組成物
AU2006313491B2 (en) Compositions and methods for treating thrombocytopenia
JP5576290B2 (ja) 白血病の管理における３−（インドリル）−または３−（アザインドリル）−４−アリールマレイミド誘導体の用途
CN101222850A (zh) 治疗对药物有抗性的癌症的方法
KR20160020502A (ko) 제약 조합물
AU2013263043A1 (en) Dosage regimen for a PI-3 kinase inhibitor
RU2304436C2 (ru) Применение производных n-фенил-2-пиримидинамина против основывающихся на мастоцитах заболеваний, подобных аллергическим нарушениям
JP2023515817A (ja) ダブラフェニブ、ｅｒｋ阻害剤及びｓｈｐ２阻害剤を含む三重の医薬品の組合せ
US20220008409A1 (en) Cancer combination therapy using quinoline carboxamide derivative
JP6840411B2 (ja) プロテインキナーゼ活性を阻害するための（ヘテロ）アリールアミド系化合物
MX2008001971A (es) Combinacion de compuestos organicos.
WO2023056020A1 (fr) Polythérapie à l'aide d'inhibiteur de ptpn11 et d'inhibiteur de kras g12c
WO2023016995A1 (fr) Compositions destinées à être utilisées dans le traitement de malignités des lymphocytes b
JPWO2019039525A1 (ja) Ａｘｌ阻害剤を有効成分として含むがん治療剤
JP2022549272A (ja) Ｅｇｆｒ阻害剤とｃｄｋ４／６阻害剤の組み合わせを用いたｅｇｆｒ変異に関連する癌の治療
WO2022063134A1 (fr) Inhibiteur de la kinase csf1r et son utilisation
TW202404600A (zh) 使用ptpn11抑制劑及pd-1/pd-l1抑制劑之組合療法
TW202342043A (zh) 使用ptpn11抑制劑及egfr抑制劑之組合療法
WO2023059785A9 (fr) Pyrimidin-4(3h)-ones substituées destinées à être utilisées dans le traitement du cancer
TW202404599A (zh) 使用經取代之嘧啶-4(3h)-酮及納武單抗(nivolumab)之組合療法
WO2023174314A1 (fr) Utilisation et procédé de traitement d'un dérivé d'azétidine
Kulasekararaj et al. The Non-transplant Treatment of Myelodysplastic Syndromes—What's on the Horizon?
JP2005508846A (ja) アレルギー性疾患のような肥満細胞系疾患に対するｎ−フェニル−２−ピリミジンアミン誘導体の使用

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period